Terms: = Lymphoma AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
250 results:
1. B-cell lymphoma with cytokine storm in serosal effusion: A case report and literature review.
Zhang X; Shi X; Liu X; Li C; Xu Z; Dai X; Ma B; Zhu X
Medicine (Baltimore); 2024 Mar; 103(10):e37400. PubMed ID: 38457551
[TBL] [Abstract] [Full Text] [Related]
2. Serum interleukin-33 and soluble suppression of tumorigenicity 2 in pediatric leukemia with febrile neutropenia.
Polat MC; Sönmez Ç; Yarali N; Özbek NY
Eur J Pediatr; 2024 May; 183(5):2155-2162. PubMed ID: 38367066
[TBL] [Abstract] [Full Text] [Related]
3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract] [Full Text] [Related]
4. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract] [Full Text] [Related]
5. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Luke JJ; Patel MR; Blumenschein GR; Hamilton E; Chmielowski B; Ulahannan SV; Connolly RM; Santa-Maria CA; Wang J; Bahadur SW; Weickhardt A; Asch AS; Mallesara G; Clingan P; Dlugosz-Danecka M; Tomaszewska-Kiecana M; Pylypenko H; Hamad N; Kindler HL; Sumrow BJ; Kaminker P; Chen FZ; Zhang X; Shah K; Smith DH; De Costa A; Li J; Li H; Sun J; Moore PA
Nat Med; 2023 Nov; 29(11):2814-2824. PubMed ID: 37857711
[TBL] [Abstract] [Full Text] [Related]
6. Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review).
Kausar MA; Anwar S; El-Horany HE; Khan FH; Tyagi N; Najm MZ; Sadaf ; Eisa AA; Dhara C; Gantayat S
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37830150
[TBL] [Abstract] [Full Text] [Related]
7. [Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day].
Ranchon F; Chatelut É; Lambert J; Sesques P; Thibault C; Madelaine I; Rioufol C; Diéras V; Cazin JL
Bull Cancer; 2023 Dec; 110(12):1343-1351. PubMed ID: 37827964
[TBL] [Abstract] [Full Text] [Related]
8. The clinical characteristics and prognosis of patients with SAPHO syndrome--a real-world cohort study.
Duan H; Gao S; Zhang L; Song L; Zhai J; Deng X
Clin Rheumatol; 2024 Jan; 43(1):561-568. PubMed ID: 37755548
[TBL] [Abstract] [Full Text] [Related]
9. Multi-Phenotypic Breast Cancer Post-Radiotherapy for Hodgkin lymphoma: A Case of Secondary Malignancy.
White D; Sadough Shahmirzadi M; Boulmay B
J Investig Med High Impact Case Rep; 2023; 11():23247096231188251. PubMed ID: 37480256
[TBL] [Abstract] [Full Text] [Related]
10. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
[TBL] [Abstract] [Full Text] [Related]
11. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Liu S; Xie SM; Liu W; Gagea M; Hanker AB; Nguyen N; Singareeka Raghavendra A; Yang-Kolodji G; Chu F; Neelapu SS; Marchese A; Hanash S; Zimmermann J; Arteaga CL; Tripathy D
Breast Cancer Res; 2023 Jun; 25(1):62. PubMed ID: 37280713
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for her2-Expressing Breast Tumors.
Vincent BG; File DM; McKinnon KP; Moore DT; Frelinger JA; Collins EJ; Ibrahim JG; Bixby L; Reisdorf S; Laurie SJ; Park YA; Anders CK; Collichio FA; Muss HB; Carey LA; van Deventer HW; Dees EC; Serody JS
J Immunol; 2023 Jul; 211(2):219-228. PubMed ID: 37204246
[TBL] [Abstract] [Full Text] [Related]
13. CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest.
Cao W; Yao S; Li A; Chen H; Zhang E; Cao L; Zhang J; Hou Y; Dai Z; Chen J; Huang X; Yang L; Cai Z
J Zhejiang Univ Sci B; 2023 May; 24(5):442-454. PubMed ID: 37190893
[TBL] [Abstract] [Full Text] [Related]
14. Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo.
Benvenuto M; Angiolini V; Focaccetti C; Nardozi D; Palumbo C; Carrano R; Rufini A; Bei R; Miele MT; Mancini P; Barillari G; Cirone M; Ferretti E; Tundo GR; Mutti L; Masuelli L; Bei R
Biol Direct; 2023 Apr; 18(1):17. PubMed ID: 37069690
[TBL] [Abstract] [Full Text] [Related]
15. Successful treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic lymphoma Kinase Fusion Gene.
Shiraishi T; Yamasaki K; Kidogawa M; Shingu T; Ujimiya F; Jotatsu T; Matsumoto S; Izumi H; Nishida C; Goto K; Yatera K
Intern Med; 2023 Nov; 62(21):3215-3221. PubMed ID: 36927974
[TBL] [Abstract] [Full Text] [Related]
16. Arrhythmogenic Cardiotoxicity Associated With Contemporary treatments of Lymphoproliferative Disorders.
Sherazi S; Schleede S; McNitt S; Casulo C; Moore JE; Storozynsky E; Patel A; Vidula N; Aktas MK; Zent CS; Goldenberg I
J Am Heart Assoc; 2023 Mar; 12(6):e025786. PubMed ID: 36892046
[TBL] [Abstract] [Full Text] [Related]
17. A CD19-Anti-erbb2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate erbb2
Hombach AA; Ambrose C; Lobb R; Rennert P; Abken H
Cells; 2023 Jan; 12(2):. PubMed ID: 36672182
[TBL] [Abstract] [Full Text] [Related]
18. Expression of TRX1 optimizes the antitumor functions of human CAR T cells and confers resistance to a pro-oxidative tumor microenvironment.
Balta E; Janzen N; Kirchgessner H; Toufaki V; Orlik C; Liang J; Lairikyengbam D; Abken H; Niesler B; Müller-Decker K; Ruppert T; Samstag Y
Front Immunol; 2022; 13():1063313. PubMed ID: 36591284
[TBL] [Abstract] [Full Text] [Related]
19. [Gastric SWI/SNF complex deletion-associated undifferentiated carcinoma with rhabdoid phenotype: a clinicopathological and molecular analysis].
Jin YP; Wang L; Wang Y; Wu DY; Zhang H; Xia QX
Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1229-1234. PubMed ID: 36480831
[No Abstract] [Full Text] [Related]
20. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic her2-expressing or her2-amplified cancers: a phase 1, dose-escalation and expansion study.
Meric-Bernstam F; Beeram M; Hamilton E; Oh DY; Hanna DL; Kang YK; Elimova E; Chaves J; Goodwin R; Lee J; Nabell L; Rha SY; Mayordomo J; El-Khoueiry A; Pant S; Raghav K; Kim JW; Patnaik A; Gray T; Davies R; Ozog MA; Woolery J; Lee KW
Lancet Oncol; 2022 Dec; 23(12):1558-1570. PubMed ID: 36400106
[TBL] [Abstract] [Full Text] [Related]
[Next]
